Clinical Trial Update: Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing gemcitabine alone versus gemcitabine plus docetaxel in unresectable soft tissue sarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma, Soft Tissue | Phase 3 | Status: COMPLETED